The big sequencing platform news this week is Roche's announcement that they are ending their collaborations aimed at developing new sequencing technologies. A collaboration with DNA Electronics aimed to create an Ion Torrent-like system whereas a more ambitious effort with IBM aimed to create instruments based on "DNA transistors". As noted by Forbes' Matthew Herper in a thought-provoking piece, Illumina is sitting very high atop the sequencer market.
A computational biologist's personal views on new technologies & publications on genomics & proteomics and their impact on drug discovery
Wednesday, April 24, 2013
Thursday, April 04, 2013
For What is a 454 Still Great?
I've been mulling this item ever since AGBT, but have struggled with the title. I don't want to sound like I have a grudge against 454 ( truth is I just got some good datasets off this technology), but I do believe that they are few papers away from being stampeded. Or perhaps not; perhaps the community is really wedded to this platform.
Subscribe to:
Posts (Atom)